Abstract
The COVID-19 pandemic has fuelled a global crisis of unmet needs for mental health care, particularly for mood and anxiety disorders.1 Recently, the question of what should be the initial treatment choice for these disorders was thoroughly addressed by Furukawa and colleagues in a systematic review.2 Their network meta-analysis of 81 randomised controlled trials, comprising 13 722 adult participants with acute depressive episodes, compared psychotherapy, antidepressant medication, their combination, standard or usual care in primary or secondary settings, or a pill placebo on remission and sustained response and showed combined treatment or psychotherapy alone outperformed all comparators, and was equally effective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
